Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19

NACompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Omicron Variant of COVID-19
Interventions
DRUG

Nirmatrelvir/Ritonavir

Patients in both groups were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time. oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body temperature \>38.5 ℃. The study group was given Nirmatrelvir 300mg/Ritonavir 100mg orally, q12h, for 5 days, and the control group not given any antiviral drugs.

Trial Locations (1)

325000

Xiangao Jiang, Wenzhou

All Listed Sponsors
lead

Xiangao Jiang

OTHER